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Abstract
Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive
tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have
been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is
involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we
will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their
preclinical and clinical applications.
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Background
Acute lymphoblastic leukemia (ALL) is an aggressive
tumor entity of highly proliferative malignant lymphoid
cells. This leukemia subtype occurs most frequently in
children with incidence peaks between 2 and 5 years of
age and is one of the most common childhood malig-
nancies worldwide [1]. Survival in ALL has improved in
clinical trials with treatment modification based on pa-
tients’ pharmacodynamics and pharmacogenomics. How-
ever, prognosis remains poor in infants and adults, and
innovative approaches are needed to further improve
survival while reducing adverse effects. Almost all human
cancer types contain epigenetic alterations that contribute
to cancer development due to the regulatory role during
transcription of epigenetic modifications in genes [2]. Dis-
turbance of correct epigenetic configuration is postulated
to act as a first seminal event in carcinogenesis lead-
ing to early abnormal clonal expansion of stem/progeni-
tor cells [2, 3].
The aberrant histone acetylation is involved in the per-
manent changes of gene expression controlling ALL
phenotype. Moreover, since histone acetylation can be
reversed, the development of drug-based treatments
for targeting proteins and enzymes involved in the
regulation of histone acetylation in ALL has become
an attractive therapeutic strategy. In this article, we
will focus on the histone acetylation associated with
ALL, their implications as biomarkers for prognostic,
and their preclinical and clinical applications.
Review
Histone acetylation
Histone acetylation and deacetylation, essential parts of
gene regulation, are the processes through which the
lysine residues within the N-terminal tail protruding
from the histone core of the nucleosome are acetylated
and deacetylated as part of gene regulation.
These reactions are typically catalyzed by enzymes
with histone acetyltransferase (HAT) or histone deacety-
lase (HDAC) activity. The major HATs are GNAT family,
MYST family, and CBP/p300 family [3, 4]. The HDACs
with four classes (classes I, II, III, and IV) include
HDAC1–11 and Sirtuins [5, 6]. Acetylation is the process
that an acetyl functional group is transferred from one
molecule to another. Deacetylation is simply the reverse
reaction that an acetyl group is removed from a molecule.
Acetylated histones of octameric proteins that organize
chormatin into nucleosomes and ultimately higher order
structures represent a type of epigenetic marker within
chromatin. Acetylation removes the positive charge on the
histones, thereby decreasing the interaction of the N ter-
mini of histones with the negatively charged phosphate
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groups of DNA. As a consequence, the condensed chro-
matin is transformed into a more relaxed structure that is
associated with greater levels of gene transcription; how-
ever, this relaxation can be reversed by HDAC activity [7].
Role of histone acetylation
Histone acetylation has been closely associated with in-
creases in transcriptional activation while deacetylation
has been linked with transcriptional deactivation and is
known as gene silencing, and histone acetylation also
causes changes in transcription activity (Fig. 1) [8–15].
Histone proteins modified by acetyl groups add negative
charges to positive lysines, thus, reducing the interaction
between DNA and histones [16–19]. This opens up the
usually tightly packed nucleosome and allows transcrip-
tion machinery to come into contact with the DNA tem-
plate, leading to gene transcription. The acetyl group is
removed by one of the HDAC enzymes during deacety-
lation, allowing histones to interact with DNA more
tightly to form compacted nucleosome assemblies, which
can effectively silence gene transcription.
Another implication of histone acetylation is to pro-
vide a platform for protein binding. As a posttransla-
tional modification, acetylation of histones can attract
proteins to elongated chromatin that has been marked
by acetyl groups. Therefore, acetyl mark provides a site
for protein recognition where transcription factors inter-
act with the acetylated histone tails via their bromodo-
main [20].
Patterns of posttranslational modifications on histones,
collectively, can direct specific cellular functions [21].
The specific addition of single or multiple modifications
on histone cores can be interpreted by transcription fac-
tors complexes, leading to functional implications [22].
Acetylation patterns of H4 histones suggested that these
modification patterns are collectively maintained during
mitosis and meiosis leading to long-term changes in
gene expression. Acetylation patterns are transmitted
and interconnected with protein binding ability and
functions in subsequent cell generation. Specific histone
site acetylation has a regulatory role in gene transcrip-
tional activation [23].
Acetylated histones represent a type of epigenetic
marker within chromatin. Modifications of histones
cannot only cause secondary structural changes at their
specific points but can also cause structural changes in
distant locations which can also affect function. As the
chromosome is replicated, modifications on the parental
chromosomes are handed down to daughter chromo-
somes. It has been shown that, expression of genes may
still be effected even past one replication and in fact has
been observed many cell generations later.
Fig. 1 Histone acetylation alters chromatin structure. Acetylation removes the positive charge on the histones with histone acetyltransferases,
which is referred to as euchromatin. As a consequence, the condensed chromatin is transformed into a more relaxed structure that is associated
with greater levels of gene transcription. However, this relaxation can be reversed by histone deacetylase, which is referred to as heterochromatin.
Acetylation has been closely associated with increases in transcriptional activation while deacetylation has been linked with transcriptional deactivation
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Altered histone acetylation enzyme
HATs
CREBBP (also called CBP) or EP300 (also called p300)
have been found fused to MLL, MOZ, and MORF. Inter-
estingly, MOZ-CBP, a fusion protein associated with
AML carrying the t(8;16)(p11, p13) translocation, is
composed of two proteins with acetylating activities:
CBP and MOZ, the latter belonging to the MYST family
of acetyltransferases [24]. The different fusion proteins
described contribute to leukemic transformation most
likely by a mechanism involving mistargeted histone
acetylation and thus aberrant activation of gene expression
[25]. In 84 % (73/86) of ALL patients, CREB is overex-
pressed at diagnosis but not in remission nor in non-
leukemia samples [26]. By contrast, the parallel expression
of the cAMP early inducible repressor (ICER), which re-
presses CREB activity by competing for the CREB consen-
sus site, appears downregulated at diagnosis but neither in
remission nor in control samples [26]. Thus, it is plausible
that CREB overexpression leads to target gene upregula-
tion and increased cell proliferation and survival that are
not counteracted by the insufficient level of ICER expres-
sion. Despite the apparently good prognosis, 15 % of high
hyper-diploid (HD) childhood ALL cases relapse and the
majority of these cases have mutations in the CREBBP
HAT domain [27, 28]. Relapse of ALL is a leading cause
of death due to disease in young people, but the reasons
for poor prognosis are still to be elucidated. Mullighan
and colleagues performed targeted resequencing of 300
genes in 23 matched relapse-diagnosis B-ALL pairs.
Genome-wide profiling of structural DNA alterations in
ALL identified multiple sub-microscopic somatic muta-
tions targeting key cellular pathways and demonstrated
evolution in genetic alterations from diagnosis to relapse
[29]. Many of the mutations that have been identified
concern the transcriptional co-activators CREBBP and
NCOR1, the transcription factors ERG, SPI1, TCF4, and
TCF7L2, components of the Ras signaling pathway, his-
tone genes, genes involved in histone modification
(CREBBP and CTCF), and genes target of DNA copy
number alterations [29]. The parallel analysis of an ex-
tended cohort of diagnosis-relapsed cases and acute
leukemia cases that did not relapse showed that the
18.3 % relapsed cases had sequence deletion or mutations
in CREBBP [27, 29]. CREBBP is expressed in leukemia
cells and normal B-cell progenitors, and the mutant
CREBBP alleles are expressed in ALL cell lines harboring
mutations. Mutations at diagnosis or acquired at relapse
consist in truncated alleles or deleterious substitutions in
conserved residues of the HATs domain, impairing
histone acetylation and transcriptional regulation of
CREBBP targets, including glucocorticoid responsive
genes. In mice, the homozygous deletion of CREBBP
or EP300 is lethal due to developmental abnormalities
whereas CREBBP(+/−) mice show defects in B lymph-
oid development and an increased incidence of
hematopoietic tumors [30]. Both CREBBP and EP300
sequence mutations have been reported in solid tumors
and, more recently, also in hematological malignancies,
whereas rare EP300 mutations have been detected in
some ALL cell lines [29, 31]. Many identified mutations
are related to transcriptional and epigenetic regulation in
ALL treatment resistance. It is worth outlining that the
high incidence of CREBBP mutations found in relapse-
prone HD ALL cases discloses the possibility of a targeted
customized treatment in this genetic subgroup [28]. Re-
cently, higher expression levels of KAT7, KAT2A, KAT6B,
and CSRP2BP were found in B-ALL; however, the
functional role of this overexpression in leukemogenesis is
unknown. Notably, it was demonstrated that KAT2A acet-
ylates the E2A-PBX1 oncoprotein (resulting from the
fusion of TCF3-PBX1 genes), increasing its stability in
B-ALL cells [32].
Histone acetylations are not only restricted to B-ALL
but also are a notable feature of T-ALL, particularly the
aggressive subtype early T cell precursor (ETP) ALL.
Whole genome sequencing of 12 cases of ETP ALL iden-
tified mutations in genes encoding components of the
polycomb repressor complex 2 (PRC2), including dele-
tions and sequence mutations of EZH2, SUZ12, and
EED [33]. Loss of function mutations and deletions of
EZH2 and SUZ12 genes have also been found in T-ALL,
where authors implicate the tumor suppressor role of
the PRC2 complex [34]. CREB activation can also have
an important role in the complex cross talk among pro-
and anti-apoptotic pathways in Jurkat T cells [35].
HDACs
Changes in histone acetylation can contribute to car-
cinogenesis through altered transcriptional regulation of
genes involved in various biological processes, such as
cell cycle regulation differentiation, apoptosis, cell adhe-
sion, and angiogenesis. Especially, increased expression
of HDACs, leading to reduced histone acetylation, is
known to be widespread among cancers. Moreno et al.
identified higher expression of several HDAC genes (i.e.,
HDAC2, HDAC3, HDAC8, HDAC6, and HDAC7) in
ALL when compared with normal bone marrow. Fur-
thermore, HDAC6 and HDAC9 were upregulated in B
cell ALL, whereas HDAC1 and HDAC4 were overex-
pressed in T cell ALL [36]. In addition, Tao et al. recently
confirmed that HDAC2 was overexpressed in ALL [37].
Moreover, increased expression of HDAC3, HDAC7, and
HDAC9 has been associated with poor prognosis in
childhood ALL, and cells from these patients were found
to display increased HDAC activity [36, 38]. H4 acetyl-
ation was recently suggested as a prognostic marker in
new ALL patients, as well as in patients at first relapse.
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Indeed, high levels of H4 acetylation were correlated
with an increased overall survival, although the authors
stated that the study has to be confirmed on a greater
number of patients and adding the analysis of H3 acetyl-
ation levels [39, 40].
Gruhn and colleagues also identified the relevance of
HDACs for childhood ALL. In this experiment, the ex-
pression of HDAC1–11 was determined in samples from
93 patients with primary ALL and eight healthy donors.
They found that HDAC1, HDAC2, and HDAC8 expres-
sion was significantly higher in ALL samples. High ex-
pression of HDAC4 was associated with a high initial
leukocyte count, T cell ALL, and poor response to pred-
nisone. These data show that HDAC4 could be a drug
target in childhood ALL, especially in those responding
poorly to prednisone [41].
In addition to the discovery of somatic mutations in
epigenetic machinery in ALL, messenger RNA (mRNA)
expression of HDACs has also been shown to be dysregu-
lated. Moreno and colleagues presented an analysis of the
mRNA levels of 12 different HDAC isoforms in childhood
ALL. HDAC2, HDAC3, and HDAC6 to HDAC8 mRNAs
were overexpressed in ALL compared with normal bone
marrow samples. HDAC1 and HDAC4 levels were also
found to be higher in T cell ALL, whereas HDAC5 mRNA
was higher in B cell ALL. This study investigates the cor-
relation of HDAC transcript levels with patient’s survival
resulting in the association of overexpression of HDAC3,
HDAC7 and HDAC9 with poor prognosis [36]. The ana-
lysis of HDAC mRNAs from ALL samples revealed an
overexpression of HDAC6 and SIRT1 and a downregula-
tion of HDAC5 [42]. Given the compelling evidence of
HDAC’s involvement in tumor development and pro-
gression, inhibitors of HDACs have emerged as an at-
tractive therapeutic option for hematologic malignancies.
Altogether, aberrant histone acetylations have been associ-
ated with disease progression and relapse of ALL and pro-
vided a molecular basis for the pharmacological use of
HDAC inhibitors (HDACis) in ALL treatment.
Histone acetylation in preclinical and clinical trials
Along with the fact that unfavorable epigenetic alter-
ations might be reversible, the indisputable role of epi-
genetics in cancer has favored the development of
novel epigenetic drugs. There are 377 known epigen-
etic proteins according to the Structural Genomics
Consortium. In recent years, several small-molecule
inhibitors have been developed to target epigenetic regula-
tors, including various HMTs (e.g., EZH2, EZH1, DOT1L,
and SUV39H1), HDMs (e.g., LSD1, LSD2, and JMJD2)
and a histone acetyltransferase (p300/CBP). However,
epigenetic-based studies have only yielded approval for
drugs affecting two classes of epigenetic regulators, DNA
methyltransferases and HDACs.
HAT inhibitors
Only a few molecules have been brought to light as
HAT inhibitors, which have not been extensively studied
in leukemia [43]. Anacardic acid, garcinol, and curcumin
have been proven to be valid natural HAT inhibitors.
The first synthetic compounds designed were coenzyme
A (CoA)-conjugated peptide analogs (e.g., LysCoA, H3-
CoA-20, and others). Subsequently, other compounds
such as garcinol analogs, the g-butyrolactone MB-3,
isothiazolones, and quinoline derivatives have been re-
ported to inhibit specific HAT members and to be ef-
fective in blocking proliferation of some solid tumor cell
lines, but the mechanism of action is still not elucidated.
A p300-specific molecule, the pyrazolone-furan C646, is
able to suppress proliferation of melanoma and lung can-
cer cell lines, reinforcing the idea that HATs are promising
targets for cancer therapy, including leukemia.
HDAC inhibitor
HDACs are a powerful new class of anticancer agents
that have the potential to restore normal histone acetyl-
ation status of cells in order to enhance gene transcrip-
tion. Different HDACis induce death of cancer cells by
different mechanisms that include changes in gene expres-
sions and alterations of both histone and non-histone pro-
teins. Enhanced histone acetylation in a variety of tumors
results in modification of expression of the genes involved
in cell signaling, which involved in several biological pro-
cesses such as cell cycle arrest and apoptosis induction
and metabolism and angiogenesis (Fig. 2) [44–48]. Many
molecules with HDAC-inhibiting activities have been
discovered in the last few years. Newer compounds
have been studied in the clinic with varying results,
such as panobinostat (LBH589), givinostat (ITF2357),
mocetinostat (MGCD01030), belinostat (PXD101), pra-
cinostat (SB939), and entinostat (MS275), the class I-
specific agents CHR-3966, chidamide (CS055/HBI-8000),
class I- and class II-specific AR-42, hydroxamides quisino-
stat (JNJ-26481585), and abexinostat (PCI-24781) [49, 50].
These inhibitors affect multiple cellular processes and
have been shown to induce differentiation, cell cycle arrest
and apoptosis. Moreover, they have been used to inhibit
cell migration, invasion, and angiogenesis in cancer
cell lines [51]. The potential importance of these
changes is highlighted by the promising activity of several
other drugs from the same class that target epigenetic al-
terations [52]. Some of which have entered clinical trials
involving hematological or solid tumors, either as mono-
therapies or in combination with other drugs [49, 53].
HDACis may be both specific against only some
HDACs (HDAC isoform-selective inhibitors) or against
all types of HDACs (pan-inhibitors). They can be classi-
fied into four groups according to their chemical struc-
ture: hydroxamic acids, aliphatic acids, benzamides, and
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cyclic tetrapeptides (Table 1) [53–55]. Hydroxamic acids
include trichostatin A, vorinostat, CBHA, LAQ-824,
PDX-101 (belinostat), LBH-589 (panobinostat), ITF-
2357, and PCI-24781 [56]. Cyclin tetrapeptides include
romidepsin (depsipeptide, FK228, FR901228), apicidin,
and trapoxin A and B [57, 58]. The aliphatic acids in-
clude valproic acid (VPA), butyric acid, AN-9 (pivanex),
and phenylbutyric acid [59]. Benzamides include enti-
nostat [SNDX-275, MS-275 (entinostat)] and moceti-
nostat (MGCD0103) [60]. However, only a few HDACis
were studied and/or approved by the FDA for the
treatment of leukemia (Table 2). These HDACis in
preclinical and clinical trials for ALL were reported
as follow.
Vorinostat
Vorinostat, also called suberoylanilide hydroxamic acid
(SAHA), blocks the enzymatic activity of both Class I
(HDAC1, HDAC2, and HDAC3) and Class II (HDAC6)
HDACs at low nanomolar concentrations (IC50 < 86 nM)
by directly binding to the catalytic site of these enzymes,
and its therapeutic properties were first demonstrated in
nude mice transplanted with human prostate tumors for
its anticancer potential [61, 62]. Recently, vorinostat has
been approved by the US Food and Drug Administration
for the treatment of cutaneous T cell lymphoma and along
with Panobinostat (LBH589), and Belinostat (PXD101),
they are undergoing clinical investigation for leukemia
[63, 64].
Fig. 2 Major mechanism of histone deacetylase inhibitors action. Enhanced histone acetylation in a variety of tumors results in modification of
expression of the genes involved in cell signaling, which involved in several biological processes such as cell cycle arrest and apoptosis induction
and metabolism and angiogenesis
Table 1 HDACis under clinical development
Chemical structure Name Target Study phase
Hydroxamates SAHA (vorinostat) Pan-inhibitor Phase III alone or in combination
PXD101 (belinostat) Pan-inhibitor Phase II alone or in combination
LBH589 (panobinostat) Pan-inhibitor Phase II alone or in combination
ITF2357 (givinostat) Pan-inhibitor Phase II alone or in combination
4SC-201 (resminostat) Pan-inhibitor Phase II alone or in combination
PCI 24781 (abexinostat) Classes I and II Phase II alone or in combination
Cyclic peptides Depsipeptide/FK228 (romidepsin) Classes I phase III alone or in combination
Aliphatic fatty acids Valproic acid Classes I and IIa Phase II alone or in combination
Butyrate Classes I and IIa Phase II alone or in combination
Benzamides MS-275 (entinostat) Class I Phase II alone or in combination
MGCD0103 (mocetinostat) Class I/IV Phase II alone or in combination
HDACis HDAC inhibitors
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Vorinostat has numerous effects on biological pro-
cesses including cell cycle progression, apoptosis, and
differentiation at the cellular level, as well as angiogen-
esis inhibition and immune response modulation at the
tissue level [61]. One model for the antitumor action of
SAHA is that its inhibition of HDAC activity, and subse-
quent accumulation of acetylated histones, leads to the
activation of genes whose expression causes induction of
differentiation or apoptosis, thus inhibiting tumor growth,
which is based on the finding that the expression of a rela-
tively small number of genes (2–10 % of expressed genes)
is regulated following exposure of tumor cells to vorino-
stat [61]. One of the most commonly induced genes is the
cyclin-dependent kinase inhibitor p21. However, rather
than promoting apoptosis in tumor cells, it appears that
vorinostat induced expression of p21 causes a cell cycle
arrest in a p53-independent manner [65]. Moreover, in-
creased acetylation of transcription factors such as p53,
HIF-1α, and E2F and increased acetylation of cytoplasmic
proteins such as α-tubulin, HSP90 and cortactin also con-
tribute to vorinostat-induced cell cycle arrest, induction of
cell death, and the inhibition of tumor growth [61].
Using two NOD/SCID mouse models, the efficacy of
vorinostat was observed in B cell precursors childhood
ALL in vivo. In fact, vorinostat was administered in a
dose of 50, 100, or 150 mg/kg for 21 days, in both sub-
cutaneous and intravenous models, and caused a clear
growth suppression of the xenograft tumors [66].
Vorinostat not only modulated the gene expression
signature characteristic of relapse in ALL cell lines and
patient samples but also showed a synergistic effect when
given sequentially with chemotherapy. Coadministration
of vorinostat plus the highly effective antileukemic drug
methotrexate (MTX) can synergize to induce apoptotic
death in ALL cells. When used as single agents, both
MTX and vorinostat can induce growth arrest, cell death,
and apoptosis. However, MTX plus vorinostat synergistic-
ally increase apoptotic cell death and decrease viability in
all B-precursor-ALL (SupB15, REH, NALM6, RCH-ACV)
and T-ALL (CCRF-CEM) cell models tested [67]. Syner-
gistic effect of vorinostat with dexamethasone in both in
vitro and in vivo models for glucocorticoid resistance is
associated with epigenetic silencing of the BIM gene in
pediatric ALL [68]. A trial studying the efficacy of the use
of decitabine and vorinostat together with combination
chemotherapy in treating patients with relapsed/refractory
ALL or lymphoblastic lymphoma with 2 to 60 years of the
age was performed [69]. Another pilot study was being
performed using vorinostat and decitabine before and dur-
ing chemotherapy with vincristine, dexamethasone, mitox-
antrone, and peg-asparaginase in pediatric patients with
relapsed ALL [70].
Numerous in vitro and in vivo studies have already
demonstrated the antileukemic activity of HDACis in
ALL, either alone or in combination with bortezomib
(proteasome inhibitor), decitabine (DNMT inhibitor),
MK-0457 (Aurora kinase inhibitor), KW-2449 (BCR-
ABL1 tyrosine kinase inhibitor), or standard chemother-
apy [66, 71–77]. However, vorinostat was evaluated in
pediatric preclinical trials and was not effective as a single
agent [78]. The mechanism of action of LBH589 in two
Ph− ALL cell lines (T cell MOLT-4 and preB cell Reh) was
investigated. Low nanomolar concentrations of LBH589
induced cell cycle arrest, apoptosis, and histone hyperace-
tylation. LBH589 treatment also increased mRNA levels of
proapoptosis, growth arrest, and DNA damage repair
genes [74]. Despite overwhelming preclinical data, very
few phase I clinical trials have been conducted to assess
HDACis in ALL and existing studies involved only a
handful of ALL patients. Specifically, a phase I study
of LBH589 included one patient with ALL, while a
phase I study of vorinostat included only two ALL
patients [79, 80]. The study found that intravenous admin-
istration of LBH589 was well tolerated at doses <11.5 mg/
m2, while higher doses induced cardiac and other toxicities
like nausea, diarrhea, vomiting, hypokalemia, loss of appe-
tite, and thrombocytopenia [79]. Therefore, there are insuf-
ficient clinical data to establish whether this class of drugs
will be efficacious in treating ALL. However, HDACis
remain as promising candidates for combination therapies
involving conventional chemotherapy or other types of in-
hibitors [81, 82].
Table 2 HDACis in clinical trials for leukemia
Chemical structure Name Target Study phase
Hydroxamates SAHA (vorinostat) Pan-inhibitor Phase I/II alone or in combination
PXD101 (belinostat) Pan-inhibitor Phase I/II alone or in combination
LBH589 (panobinostat) Pan-inhibitor Phase I/II alone or in combination
Cyclic peptides Depsipeptide/FK228 (romidepsin) Classes I Phase I/II alone or in combination
Aliphatic fatty acids Valproic acid Classes I and IIa Phase II alone or in combination
Butyrate Pan-inhibitor Phase I/II alone or in combination
Benzamides MS-275 (entinostat) Class I Phase I alone or in combination
MGCD0103 (mocetinostat) Class I/IV Phase I alone or in combination
HDACis HDAC inhibitors
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Aliphatic fatty acids
Some compounds of natural origin have been initially
isolated for their ability of inhibiting deacetylation. So-
dium butyrate and trichostatin A are the prototypes of
two families of inhibitors, chemically classified as short-
chain fatty acids and hydroxamic acids, respectively.
Trichostatin A can induce apoptosis of ALL cell lines
including Sup-B15, TMD-5, SEM, and NALM-6 [83].
Sodium butyrate exhibits a short half-life that limits its
therapeutic application; however, from its structure,
other more promising molecules have been developed,
in particular, sodium phenylbutyrate and AN-9 (Pivanex),
which demonstrated selective toxicity for leukemia cells
against healthy blood cells [84, 85]. AN-9 is a relatively
new member of an established family of acyloxyalkyl ester
prodrugs of carboxylic acids that undergo rapid hydrolysis,
and its anticancer effect is assumed to stem primarily
from the release of butyric acid [83]. AN-9 has antipro-
liferative and cytotoxic effects on a doxorubicin-resistant
T-ALL and a relapsed infant ALL characterized by an
11q23 rearrangement and a very poor prognosis. The
mechanism behind the antiproliferative effect of AN-9 ap-
peared to be generally p21-independent, and the increased
apoptosis was thought to be mediated through the reduc-
tion in the expression of antiapoptotic bcl2 gene or alter-
natively through the induction of genes involved in the
death receptor pathway [85]. At present, no clinical trial
was studied on the role of AN-9 on the treatment of ALL
in clinic.
Valproic acid
Another well-known short-chain fatty acid is valproic
acid (VPA), a derivative of valeric acid commonly used
to treat epilepsy which demonstrates selective inhibition
of class I and IIa HDACs [86]. Although VPA is a weak
HDACis, its long-term availability as an antiepileptic
drug prompted its evaluation on oncology as an epigen-
etic acting drug. VPA can inhibit the proliferation and
increase the apoptosis of Jurkat T cells in concentration-
dependent manner [87]. VPA also inhibits proliferation,
and induces apoptosis and histone H4 hyperacetylation
in B cell precursor-ALL cell lines (Reh, Nalm6, Z33) in
vitro [76]. Moreover, the administration of VPA reduces
the tumor growth significantly in two NOD/SCID mouse
models of B cell precursor-ALL. The study showed that
VPA treatment was able to inhibit the leukemia-induced
splenomegaly of animals after intravenous challenge with
ALL blasts, while no apparent toxicity was detected [74].
Several studies showed that VPA is more efficacious in
combination with other agents [88, 89]. VPA can increase
responsiveness of Philadelphia-positive cell lines to cytara-
bine [90]. Although phase I/II studies of VPA monother-
apy or in combination have been completed in adult
patients, the patients of these trials came from acute
myeloid leukemia [91]. Many studies also suggested that
VPA affects hematopoiesis, inducing anemia in epileptic
patients and impairing the erythroid differentiation
while stimulating the myelo-monocytic pathway [92].
Benzamides
Benzamides including entinostat (MS-275 or SNDX-275)
and mocetinostat (MGCD103) are another class of mole-
cules that demonstrate specificity for class I HDACs. Enti-
nostat is a novel and orally available synthetic benzamide
HDACis that preferentially inhibits HDAC1 but does not
possess activity against HDAC6 [93]. Entinostat exerts
dose-dependent effects on Jurkat T cell line: a p21-
dependent growth arrest and differentiation at low drug
concentrations and a marked induction of reactive oxygen
species, mitochondrial damage, caspase activation, and
apoptosis at higher concentrations [94]. Entinostat
can increase the apoptosis in Jurkat T cell line and
significantly improve the histone acetylation combined
with 5-azacytidine [95]. The interaction between MS-
275 and fludarabine in lymphoid and myeloid human
leukemia cells was examined, and the results demon-
strated that sequential treatment of Jurkat T cell line
with MS-275 and fludarabine induces mitochondrial
injury, caspase activation, and apoptosis [96]. How-
ever, entinostat and mocetinostat were mainly studied
in acute myeloid leukemia, relapsed and refractory
lymphoma, and chronic lymphocytic leukemia in the
clinical trials.
Conclusions
Epigenetic modifications are currently considered as
fundamental hallmarks of human cancer, playing a piv-
otal role in tumorigenesis [97]. It is now widely accepted
that epigenetic and genetic alterations collaborate in the
development and maintenance of ALL [98]. Histone
acetylation is potentially reversible, making them a
valuable target in the fight against ALL. Therefore, many
efforts have focused on designing and developing small-
molecule inhibitors for reverting undesirable histone
acetylation in ALL. Although ALL therapies based on
HATs and HDACis seem promising, there are insuffi-
cient clinical data to establish whether this class of drugs
will be efficacious in ALL treatment [98]. Knowledge
related to the functional outcomes of histone acetylation
in ALL has been indirectly derived through the use of
inhibitors, signifying that many histone acetylation
targets remain to be discovered and exploited. Despite
significant advances, the future study still holds chal-
lenges including lack of predictive biomarkers, non-
specificity of broad-spectrum histone acetylation drugs,
and ambiguous mechanisms for therapeutic response/re-
sistance [99].
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The epigenetic modifications in ALL include DNA
hypermethylation and histone modifications. Recently, it
has become clear that the DNA and histone lysine
methylation systems are highly interrelated and rely
mechanistically on each other for normal chromatin
function [100, 101]. It also showed that the combination
of HDACis with other epigenetic agents, such as DNA
methyltransferase inhibitors, can produce encouraging
clinical and biologic activity [102]. Therefore, better out-
comes could be achieved on the combination of HDACis
with other epigenetic agents in the treatment of ALL.
In summary, histone acetylation is an extremely prom-
ising area of research that holds endless potential for
future achievement in ALL. However, we have only seen
the tip of the iceberg, and there are many crucial ques-
tions that remain to be answered.
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